Tonix Pharmaceuticals stock halted ahead of FDA approval news
Amneal Pharmaceuticals (NASDAQ:AMRX) Director Gautam Patel sold 94,906 shares of Class A Common Stock on June 16, 2025, for approximately $761,146. The sales occurred at prices ranging from $8.00 to $8.05 per share, close to the current trading price of $7.94. The $2.49 billion pharmaceutical company has shown strong revenue growth of ~13% over the last twelve months, and InvestingPro analysis indicates the stock is currently undervalued.
Following the transaction, Patel directly owns 1,609,144 shares of Amneal Pharmaceuticals. Analysts maintain a bullish outlook on the company, with price targets ranging from $11 to $12 per share. InvestingPro data shows the company maintains a GREAT financial health score and is expected to turn profitable this year.
The sale was executed automatically under a pre-arranged trading plan adopted on August 15, 2024, intended to comply with Rule 10b5-1(c).
Denis Butkovic, Attorney-in-Fact, signed the Form 4 on behalf of Patel on June 18, 2025.
In other recent news, Amneal Pharmaceuticals reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted EPS of $0.21 against the forecasted $0.15, although revenue fell short at $695 million compared to the anticipated $726.49 million. The company received U.S. Food and Drug Administration approval for its Brekiya autoinjector, the first dihydroergotamine autoinjector for migraines, expected to be available in the second half of 2025. Additionally, the FDA approved Amneal’s prednisolone acetate ophthalmic suspension, with a commercial launch planned for the third quarter of 2025. Goldman Sachs initiated coverage on Amneal Pharmaceuticals with a Neutral rating, highlighting the company’s strong product pipeline as a key driver of anticipated growth. The analysts expect Amneal’s generics segment to exceed consensus estimates by 13% in fiscal year 2027, driven by biosimilar and sterile injectable launches. Amneal’s strategic focus on biosimilars and complex generics continues to be a priority, with the company positioning itself as a leader in these areas. These developments reflect Amneal’s ongoing efforts to expand its product portfolio and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.